TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07733180: A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as First-line Treatment in Japanese Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carc

Sponsor: BeOne Medicines · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,041,800

Rescue Site Savings

+$7,299,600

Unlock Full NCT07733180 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07733180 Rescue Dossier →